How were the quarterly numbers of Cipla Ltd for the fourth quarter?
Answer
Answer
Cipla reported 14.2% growth in sales for Q4FY22 at Rs5,260 crore with full year revenues growing by 13.6% at Rs21,763 crore. For the fourth quarter, Cipla saw 16% growth in R&D spending. Its now popular One-India initiative saw growth across core therapies at 21%. The North American business saw 17% dollar growth on strong traction across respiratory portfolio and peptide unlocking. API business was down -41% yoy as is the global trend.
Cipla
Rs in Crore
Mar-22
Mar-21
YOY
Dec-21
QOQ
Total Income (Rs cr)
₹ 5,260.33
₹ 4,606.45
14.19%
₹ 5,478.86
-3.99%
Net Profit (Rs cr)
₹ 362.07
₹ 413.38
-12.41%
₹ 728.60
-50.31%
Diluted EPS (Rs)
₹ 4.48
₹ 5.12
₹ 9.02
Net Margins
6.88%
8.97%
13.30%
Net profits for Q4FY22 were lower by -12.41% at Rs362 crore even as they managed to achieve a sharp reduction in debt by more than half to Rs824 crore. EBITDA fell -4% at Rs763 crore and EBITDA margins tapered by 279 bps to 14.5%. API business contributed a good deal to the fall in profits in the quarter. Net margins stood at 6.88% in Q4FY22 quarter compared to 8.97% in Q4FY21 and 13.3% in Q3FY22.